United States-based Resolve Therapeutics has revealed results from its phase two study of RSLV-132 intended for the treatment of primary Sjogren's syndrome (pSS), an autoimmune disease that primarily affects women, it was reported on Wednesday.

The leading rheumatology journal, Arthritis and Rheumatology (doi.org/10.1002/art.41489) has published the work.

The phase two study has indicated a clinically meaningful improvement in four separate, independent, validated measures of fatigue in the product group, but not the placebo group. The product is a novel, targeted biologic drug aimed at removing pro-inflammatory nucleic acids from the circulation of patients, which is the main reason for multiple pro-inflammatory cascades.

'Up to 75% of pSS patients report profound fatigue as the most debilitating aspect of pSS, so we are pleased that RSLV-132 was able to significantly improve fatigue in this study,' said James Posada, PhD, CEO of Resolve Therapeutics. 'These results represent a potential step forward in the treatment of Sjogren's syndrome, Resolve will confirm the finding in a large Phase 3 study starting in early 2021.'